JPMORGAN CHASE & CO - NABRIVA THERAPEUTICS PLC ownership

NABRIVA THERAPEUTICS PLC's ticker is and the CUSIP is G63637113. A total of 25 filers reported holding NABRIVA THERAPEUTICS PLC in Q2 2022. The put-call ratio across all filers is - and the average weighting 0.0%.

Quarter-by-quarter ownership
JPMORGAN CHASE & CO ownership history of NABRIVA THERAPEUTICS PLC
ValueSharesWeighting
Q1 2022$1,0003,224
+8613.5%
0.00%
Q1 2021$0370.0%0.00%
Q4 2020$0370.00%
Other shareholders
NABRIVA THERAPEUTICS PLC shareholders Q2 2022
NameSharesValueWeighting ↓
ABG Innovation Capital Partners III GP Ltd 45,849$8,0000.60%
Aisling Capital Management LP 90,000$16,0000.01%
Frazier Life Sciences Management, L.P. 425,650$77,0000.01%
Values First Advisors, Inc. 43,728$8,0000.01%
Virtu Financial LLC 127,585$23,0000.00%
CCG WEALTH MANAGEMENT, LLC 10,000$2,0000.00%
Running Point Capital Advisors, LLC 10,000$2,0000.00%
WELLS FARGO & COMPANY/MN 125$00.00%
CONCOURSE FINANCIAL GROUP SECURITIES, INC. 0$00.00%
GEODE CAPITAL MANAGEMENT, LLC 42,738$7,0000.00%
View complete list of NABRIVA THERAPEUTICS PLC shareholders